Nosa Plugs AB (publ), a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, Europe, North America, Oceania, and internationally. It offers NOSA smell training, a smell training medical device to improve the sense of smell for individuals with parosmia and hyposmia; NOSA odor control, which reduces bad odor; NOSA microbial control that reduces the exposure of viruses and bacteria by inhalation through the nose; NOSA Nozoil original, a moisturizing nasal spray for people suffering from dry nasal mucosa; and NOSA Cerevia, a nasal drug delivery platform for controlled administration of drugs. The company was incorporated in 2014 and is headquartered in Stockholm, Sweden.…
Analyst Group: Analyst Group Comment on Nosa Plugs' Exclusive Distribution Agreement in Morocco
Nosa Plugs (STO: NOSA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 0.4560 SEK on 20 November 2026, down 12.3% over 52 weeks. Its 52-week range is 0.3505 SEK to 0.7290 SEK: the price is 37.4% below the high and 30.1% above the low.
Its market capitalisation is 118.64M SEK.
Nosa Plugs reports return on equity of -19.6%, an operating margin of -13.0% and revenue up 180.3% year over year.
It holds more cash than debt, a net cash position of 10.24M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.